Fractyl Health, Inc. (NASDAQ:GUTS) Sees Large Drop in Short Interest

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) saw a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 2,400,000 shares, a decline of 12.1% from the January 15th total of 2,730,000 shares. Based on an average trading volume of 355,300 shares, the short-interest ratio is currently 6.8 days. Approximately 11.6% of the company's stock are sold short.

Insider Buying and Selling

In other news, insider Jay David Caplan sold 22,346 shares of the firm's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $1.81, for a total transaction of $40,446.26. Following the sale, the insider now owns 153,544 shares of the company's stock, valued at $277,914.64. This trade represents a 12.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Harith Rajagopalan sold 90,972 shares of the firm's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $1.82, for a total transaction of $165,569.04. Following the sale, the chief executive officer now directly owns 491,329 shares in the company, valued at approximately $894,218.78. The trade was a 15.62 % decrease in their position. The disclosure for this sale can be found here.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of GUTS. SG Americas Securities LLC purchased a new position in shares of Fractyl Health during the 3rd quarter worth $33,000. Beta Wealth Group Inc. purchased a new stake in Fractyl Health in the 3rd quarter worth approximately $44,000. Massachusetts Financial Services Co. MA increased its holdings in Fractyl Health by 4.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company's stock worth $2,646,000 after acquiring an additional 49,289 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Fractyl Health by 56.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company's stock worth $204,000 after acquiring an additional 29,262 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Fractyl Health by 54.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company's stock worth $53,000 after acquiring an additional 7,397 shares in the last quarter.

Analysts Set New Price Targets

Separately, Morgan Stanley reduced their price objective on Fractyl Health from $18.00 to $10.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd.

Fractyl Health Stock Performance

Shares of Fractyl Health stock traded down $0.04 on Friday, hitting $1.42. 127,149 shares of the company's stock were exchanged, compared to its average volume of 364,852. The company has a 50-day simple moving average of $1.84 and a 200-day simple moving average of $2.31. The stock has a market capitalization of $68.30 million and a PE ratio of -0.12. Fractyl Health has a 1 year low of $1.37 and a 1 year high of $10.50. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.